Last updated: March 7, 2023
Sponsor: Beijing Airdoc Technology Co., Ltd.
Overall Status: Active - Recruiting
Phase
N/A
Condition
Myopia
Treatment
N/AClinical Study ID
NCT05756959
Xuzhou First People's Hospital
Ages 6-13 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Informed consent by the supervision of the children
- 6~13 years old (including both the 6 and 13)
- SE range: -0.50~-5.50D
- Astigmatism <=2.00D
- BCVA >=0.8
- Anisometropia <=1.50D
- Confirmed to no use of other myopia control intervention
Exclusion
Exclusion Criteria:
- Ocular lesions to effect vision or diseases (such as cataract, glaucoma, marcularpathology, cornea lesions, uveitis, retina detachment, congential opitc abnormal andetc.)
- Halo, glare, toutic, ADHD, psoriasis
- Systom disease: immune disease, central nerve system, Down syndrome, asthma, severecardiopulmonary abnormal, severe liver and renal dysfunction.
- Squint, ocular lesion or acute imflammation.
- Other myopia control interventions within recent 3 month such as atropine, device,orthokeratology, multi-focus soft lens, multi-function spectacles.
Study Design
Total Participants: 304
Study Start date:
December 12, 2022
Estimated Completion Date:
December 31, 2027
Study Description
Connect with a study center
the first people's hospital of Xuzhou
Xuzhou, Jiangsu 210000
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.